About Biomunex PharmaceuticalsBiomunex is a biopharmaceutical company focused on the discovery and development of innovative bispecific antibody therapeutics, based on a proprietary platform, to address unmet medical needs in the treatment of cancer.
Founder and CEO: Dr. Pierre-Emmanuel Gerard
CSO: Dr. Eugene Zhukovsky
Please click here for Biomunex's job opportunities.
TECHNOLOGY & Products:
Please click here for Biomunex's technology.
4 articles with Biomunex Pharmaceuticals
Onward Therapeutics and Biomunex Pharmaceuticals Enter into a Worldwide Exclusive License and Co-development Agreement to a Bispecific Antibody for Immuno-Oncology
Onward Therapeutics SA announced the execution of a worldwide exclusive license and co-development agreement with Biomunex Pharmaceuticals SAS, Paris, France, of a bispecific antibody targeting two immune checkpoints.
Biomunex Inc. to focus on R&D and business development activities in the US
Biomunex Pharmaceuticals signs a licensing agreement with Sanofi for the development of bi- and multi-specific antibodies
Under the terms of the agreement, Sanofi will have access to Biomunex' proprietary technology to generate and optimize bi- and multi-specific antibody therapeutics.
Biomunex Appoints Dr. Sebastian Amigorena And Dr. Dragan Grabulovski As Key Scientific And Strategic Advisors